Progression index; relapse rate

Strong support for modulation of MS severity by s4


Table 3 Studies Assessing Impact of APOE on Disease Severity in Multiple Sclerosis (Continued)

Adverse effect

References Country Polymorphism(s) Dataset Severity assessment Authors' conclusions of e4?

Masterman et al. Sweden s2-4 264 MS

Schreiber et al. (113) Denmark s2-4 70 MS

Enzinger et al. (114) Austria s2-4 72 RRMS

Guerrero et al. (115) Spain s2-4 42 MS

Niino et al. (116) Japan s2-4 135 BOMSa

Savettieri et al. (117) Italy promoter-491, 428 MS


Dichotomization based on EDSS and duration; time to EDSS 7.0 Comparison of opposite septiles of disability-stratified cohort Progression index; T2-weighted MRI lesion load/duration EDSS; relapse rate; iV-acetylaspartate levels on ^-MRS Progression index; relapse rate

Progression index; dichotomization based on EDSS after 10 years' duration Progression index s4 associated with "severe MS" and Yes s2 with "mild MS"

Odd ratios conferred by s4 carriage Yes rise in increasingly antipodal quantiles

No confirmation of association No between s4 carriage and disease progression In vivo evidence of more extensive Yes axonal damage in s4 carriers

No confirmation that s4 is predictor No of disability progression No association between genotypes No and disease severity

No confirmation of association No between s4 and disease severity

De Stefano et al. Italy

Enzinger et al. (120) Austria

Zakrzewska-Pniewska et al. (122) Zwemmer et al. (123)

Pinholt et al. (124)

Portugal Poland



3 promoter SNPs, s2-4







Was this article helpful?

0 0

Post a comment